52nd week of 2021 patent applcation highlights part 31 |
Patent application number | Title | Published |
20210403870 | Methods and Systems for In Vitro Cardiac Disease Modeling - A method for generating an in vitro cardiac tissue model. The method includes steps of: forming an elongated tissue by disposing a plurality of cardiomyocytes within a culture plate; culturing the tissue such that each end of the elongated tissue contacts one of a pair of attachment wires adhered to the culture plate; and electrically stimulating the elongated tissue in culture. | 2021-12-30 |
20210403871 | METHODS OF PRODUCING POPULATIONS OF MESENCHYMAL STEM CELLS FROM PERIPHERAL BLOOD AND USES THEREOF - Disclosed herein are methods for providing a population of undifferentiated human mesenchymal stem cells (hMSCs). The methods include steps of, obtaining peripheral blood from a donor, adding glycerin to the peripheral blood, separating hMSCs from other somatic stem cells in the peripheral blood, and culturing the hMSCs in a medium containing glycerin thereby generating the population of undifferentiated hMSCs suitable for transplantation. | 2021-12-30 |
20210403872 | METHODS OF TREATMENT USING PLURIPOTENT HUMAN ADIPOSE ADULT STEM CELLS - Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cultured with the adipocyte fraction. PASCs can be isolated with a high degree of purification without requiring an additional cell enrichment process (e.g. cell sorting). PASCs and their conditioned media can be used for tissue regeneration within hours of harvesting the adipose tissue, and without requiring cell expansion. PASCs can grow as floating individual cells, as clusters of cells, or attached to surface(s) of the culture vessel. PASCs do not produce teratomas in vivo, nor do they induce immunorejection upon transplantation, and they achieve a high efficiency in grafting. The cells and compositions can be used for cell therapy and to screen new drugs. | 2021-12-30 |
20210403873 | METHOD OF PREPARING MESENCHYMAL-LIKE STEM CELLS AND MESENCHYMAL-LIKE STEM CELLS PREPARED THEREBY - Disclosed is a method for effectively preparing mesenchymal-like stem cells, the method including: preparing human pluripotent stem cells cultured to passage 70 or lower after establishment of cell lines; inducing differentiation of the human pluripotent stem cells to produce embryoid bodies and selecting cystic embryoid bodies therefrom; loading the cystic embryoid bodies on a cell-permeable three-dimensional (3D) culture unit to isolate mesenchymal-like stem cells therefrom; isolating only monolayer-shaped cell clusters from the mesenchymal-like stem cells passing through the cell-permeable 3D culture unit; and uniformizing sizes of the monolayer-shaped cell clusters, in which the mesenchymal-like stem cells have anti-inflammatory efficacy and immunosuppression. Further, disclosed are mesenchymal-like stem cells prepared by the preparation method, a transporter or a therapeutic composition including the mesenchymal-like stem cells, and a composition for prevention or treatment of diseases that includes an active ingredient or exosomes secreted from the mesenchymal-like stem cells. | 2021-12-30 |
20210403874 | Method for Producing Stem/Precursor Cells, By Using Low Molecular Weight Compound, From Cells Derived From Endodermal Tissue or Organ - The present invention provides a method starting from cells derived from a mammalian endodermal tissue or organ (except for the liver) to produce stein/progenitor cells thereof, which comprises bringing the cells derived from the endodermal tissue or organ into contact in vitro with a TGFβ-receptor inhibitor. | 2021-12-30 |
20210403875 | STEM CELL DERIVED ISLET DIFFERENTIATION - Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells. | 2021-12-30 |
20210403876 | STEM CELL DERIVED ISLET DIFFERENTIATION - Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells. | 2021-12-30 |
20210403877 | Composition For Inducing Dedifferentiation From Somatic Cells To Induced Pluripotent Stem Cells And Method of Inducing Dedifferentiation Using Same - The present invention relates to a composition for inducing dedifferentiation form somatic cells to induced pluripotent stem cells (iPSs) and method of inducing dedifferentiation using same, wherein the composition for inducing dedifferentiation and the method of inducing dedifferentiation increases the efficiency of dedifferentiation from somatic cells to iPSs by stimulating CXC chemokine receptor 2 (CXCR2), which is a receptor on human somatic ells, and thus may be effectively used for inducing the dedifferentiation to iPSs. | 2021-12-30 |
20210403878 | INDUCTION OF PLURIPOTENT CELLS - The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells. | 2021-12-30 |
20210403879 | METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS - The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus. | 2021-12-30 |
20210403880 | COMPUTATIONAL REDUCTION VACCINE FOR COVID-19 BIN100 - A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments 100 base pairs or greater in length; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments. | 2021-12-30 |
20210403881 | COMPOSITIONS AND METHODS FOR INTERNAL CONTROLS OF MICROVESICLE ISOLATIONS - The present disclosure provides compositions, methods and kits for internal controls of microvesicle isolations. The compositions, methods and kits can comprise enveloped viruses, including, but not limited to, inactive mouse hepatitis virus (MHV). | 2021-12-30 |
20210403882 | RECOMBINANT ACID-RESISTANT YEAST HAVING IMPROVED LACTIC-ACID-PRODUCING ABILITY - Disclosed are a recombinant acid-resistant yeast having improved lactic-acid-producing ability and a method of preparing lactic acid using the same. When producing lactic acid using the recombinant acid-resistant yeast according to the present invention, not only lactic-acid fermentation can be performed with lactic-acid-producing ability similar to that of bacterial fermentation using a remarkably smaller amount of a neutralizing agent than in the case of conventional bacterial fermentation, but also the production of ethanol and glycerol which are byproducts can be reduced. Thus, fermentation costs can be greatly reduced and the cost of subsequent purification processes can be reduced. | 2021-12-30 |
20210403883 | METHANE MONOOXYGENASE ENZYMES - Improved soluble methane monooxygenases and soluble methane monooxygenase systems are provided. | 2021-12-30 |
20210403884 | Diacylglycerol Acyltransferase 1 and Application Thereof in Production of Triacylglycerol - Disclosed is a diacylglycerol acyltransferase 1, a recombinant | 2021-12-30 |
20210403885 | CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY - Chimeric polypeptides including (a) an extracellular targeting domain; (b) a transmembrane domain; (c) an intracellular linker for activation of T cells (LAT) domain or SLP-76 domain; and (d) an intracellular ZAP70 domain, wherein (a)-(d) are in N-terminal to C-terminal order are provided. Chimeric polypeptides including (a) an extracellular targeting domain; (b) a transmembrane domain; and (c) a ZAP70 domain, wherein (a)-(c) are in N-terminal to C-terminal order are also provided. In some embodiments, the chimeric polypeptide further includes a hinge domain, a signal sequence domain, and/or an intracellular signaling domain. Nucleic acid molecules encoding the chimeric polypeptides and expression vectors including the nucleic acids are also provided. Isolated cells (such as T cells or natural killer cells) expressing the chimeric polypeptides and methods of treating a subject with cancer with the isolated cells are provided. | 2021-12-30 |
20210403886 | INTERNAL PROTEIN TAGS - Provided herein are substantially non-luminescent peptide/polypeptide tags that are inserted internally within a protein of interest or between N-terminal and C-terminal peptides/polypeptides. Interaction of the internally-inserted tag with a complement polypeptide/peptide that is also substantially non-luminescent results in the formation a bioluminescent reporter complex. | 2021-12-30 |
20210403887 | EVOLUTION OF TALENS - Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts. One current drawback of TALEs is that the 5′ nucleotide of the target is specific for thymine (T). TALE domains with alternative 5′ nucleotide specificities could expand the scope of DNA target sequences that can be bound by TALEs. Another drawback of TALEs is their tendency to bind and cleave off-target sequence, which hampers their clinical application and renders applications requiring high-fidelity binding unfeasible. This disclosure provides methods and strategies for the continuous evolution of proteins comprising DNA-binding domains, e.g., TALE domains. In some aspects, this disclosure provides methods and strategies for evolving such proteins under positive selection for a desired DNA-binding activity and/or under negative selection against one or more undesired (e.g., off-target) DNA-binding activities. Some aspects of this disclosure provide engineered TALE domains and TALEs comprising such engineered domains, e.g., TALE nucleases (TALENs), TALE transcriptional activators, TALE transcriptional repressors, and TALE epigenetic modification enzymes, with altered 5′ nucleotide specificities of target sequences. Engineered TALEs that target ATM with greater specificity are also provided. | 2021-12-30 |
20210403888 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid. | 2021-12-30 |
20210403889 | CRISPR-CAS SYSTEM FOR CLOSTRIDIUM GENOME ENGINEERING AND RECOMBINANT STRAINS PRODUCED THEREOF - A system for modifying the genome of | 2021-12-30 |
20210403890 | ALPHA-AMYLASE VARIANTS HAVING IMPROVED PERFORMANCE AND STABILITY - The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 2021-12-30 |
20210403891 | RECOMBINANT EXTRACELLULAR CHITINASE FROM BREVIBACILLUS LATEROSPORUS FOR BIOLOGICAL CONTROL AND OTHER INDUSTRIAL USES - The present invention discloses a recombinant modified extracellular chitinase having an amino acid sequence set forth in SEQ ID NO.4 or SEQ ID NO.5 prepared by substituting two tyrosine (Y) residues with histidine (H) in the native chitinase of | 2021-12-30 |
20210403892 | METHOD FOR PURIFYING AND QUANTIFYING THROMBIN AND ITS DEGRADATION POLYPEPTIDES - Provided is a method for purifying α-thrombin and for quantifying α-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified α-thrombin. The method can also be used for purification and/or quantification of β-thrombin. | 2021-12-30 |
20210403893 | HIGHLY ACTIVE S-CYANOHYDRIN LYASE AND APPLICATION THEREOF - The invention provides a highly active S-cyanohydrin lyase obtained by mutating an amino acid residue at position 103 of a wild-type cassava S-cyanohydrin lyase. The mutation can significantly increase an expression of a mutant enzyme in | 2021-12-30 |
20210403894 | Alginate Lyase and Application thereof - The disclosure discloses an alginate lyase and application thereof, and belongs to the technical field of biology. The alginate lyase provided by the disclosure has high degradation activity, and the enzyme activity reaches 65 U/mg; the alginate lyase is stable in nature, and the enzyme activity remains 98% or higher of the initial enzyme activity after storage at 4° C. for 18 months; and the alginate lyase has high product specificity. The disclosure uses | 2021-12-30 |
20210403895 | Double Enzyme Tandem Preparation Method of L-2-Aminobutyric Acid - Disclosed is a double enzyme tandem preparation method of L-2-aminobutyric acid, and belongs to the field of bioengineering. In the disclosure, recombinant | 2021-12-30 |
20210403896 | METHOD FOR IMMOBILIZING MALODOROUS MICROORGANISMS ON SURFACE OF EVAPORATOR - The present disclosure relates to a method for pretreating an evaporator for accelerating odor reproduction of an odor reproduction device for a vehicle air conditioning system, and a method for pretreating an evaporator surface of the present disclosure may include: a step of preparing an inoculation of malodorous microorganisms; a step of preparing and pretreating an evaporator; and a step of immobilizing malodorous microorganisms on an evaporator surface. | 2021-12-30 |
20210403897 | CHEMICAL ENGINEERING OF ERYTHROCYTES TO DISPLAY POLYPEPTIDES AND OTHER BIOMACROMOLECULES - Methods and materials for generating and using complexes that contain erythrocytes coupled to polypeptides, and particularly to erythrocyte-polypeptide complexes that can interact with biological molecules, are provided herein. | 2021-12-30 |
20210403898 | COMPOSITIONS, SYSTEMS, AND METHODS FOR BASE DIVERSIFICATION - Described herein are methods of modifying or editing a target nucleic acid such as methods that edit adenine to cytosine, thymine, or guanine. Compositions and systems for modifying or editing a target nucleic acid are also described. Methods, compositions and systems described herein may be used for generating allelic diversity. | 2021-12-30 |
20210403899 | METHODS FOR THE SELECTION OF BINDING PROTEINS - This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes. | 2021-12-30 |
20210403900 | Protein scaffold - The invention provides a protein scaffold and methods of preparing, screening, engineering and using the protein scaffold. | 2021-12-30 |
20210403901 | TARGETED MUTAGENESIS USING BASE EDITORS - The present invention relates to novel methods for discovering traits and generating cellular systems having improved phenotypes. In particular, the present invention provides methods for the development of plants having agronomically optimized phenotypes by using targeted mutagenesis with few or no off-target effects. Targeted mutagenesis is achieved by the introduction of a base editor complex or of a STEME complex comprising an array of guide RNAs targeting a nucleic acid sequence of interest. The present invention also relates to cellular systems obtained by the methods described herein and to the use of a base editor complex or the STEME complex comprising an array of guide RNAs for generating a cellular system having an agronomically important phenotype and for identification of an agronomically important phenotype. | 2021-12-30 |
20210403902 | Methods of Selecting and Detecting Binding Peptides - Methods for selecting, detecting, and/or enriching peptides that bind a target are provided. | 2021-12-30 |
20210403903 | MICROBEADS FOR TAGLESS ENCODED CHEMICAL LIBRARY SCREENING - Disclosed is an encoded chemical library microbead, which microbead has immobilized thereon and/or therein: (i) an encoding tag; and (ii) a target assay system reporter moiety, wherein the reporter moiety exists in a first state in the absence of activity against the target and in a second state in the presence of said activity, and wherein said microbead further comprises a clonal population of one or more chemical structure(s) releasably linked thereto and encoded by said tag. | 2021-12-30 |
20210403904 | METHODS FOR HAPLOTYPING WITH SHORT READ SEQUENCE TECHNOLOGY - Provided herein are compositions and methods for preserving proximity data in nucleic acid samples, by embedding indexing information in the samples prior to fragmentation. Further provided herein are transposon libraries for generating such indexed nucleic acid samples. | 2021-12-30 |
20210403905 | MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A - The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell. The present application also provides one or more gRNAs or sgRNAs for editing an USH2A gene containing an IVS40 mutation. The present application provides a therapeutic for treating a patient with Usher Syndrome Type 2A. The present application also provides a kit for treating a patient with Usher Syndrome Type 2A. | 2021-12-30 |
20210403906 | GENE-EDITING SYSTEMS FOR EDITING A CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR (CFTR) GENE - Described herein are highly efficient gene-editing systems comprising a nuclease, a guide RNA, and/or a donor template and uses thereof for editing a cystic fibrosis transmembrane regulator (CFTR) gene either in vitro or in vivo. | 2021-12-30 |
20210403907 | ARC-BASED CAPSIDS AND USES THEREOF - Disclosed herein, in certain embodiments, are recombinant Arc and endogenous Gag polypeptides, and methods of using recombinant Arc and endogenous Gag polypeptides. | 2021-12-30 |
20210403908 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION - Described are RNA interference (RNAi) agents for treating a Hepatitis D Virus (HDV) infection in a subject in need thereof. | 2021-12-30 |
20210403909 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION - The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs. | 2021-12-30 |
20210403910 | ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES - Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy. | 2021-12-30 |
20210403911 | CONTROL OF INSECT INFESTATION - Provided herein are methods for using RNAi molecules targeting a proteasome beta 5 (PSMB5) gene for controlling Coleopteran insects, methods for producing RNAi molecules targeting PSMB5, and compositions comprising RNAi molecules targeting PSMB5. | 2021-12-30 |
20210403912 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PESTS - Disclosed herein are polynucleotides, compositions, and methods for controlling insect pests, especially flea beetles, such as | 2021-12-30 |
20210403913 | CXCL8 Binding Nucleic Acids - The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′ [SEQ. ID. NO: 27], wherein Xu is U or absent. | 2021-12-30 |
20210403914 | SPECIFIC siRNA MOLECULES, COMPOSITION AND USE THEREOF FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER - The present invention generally relates to the field of molecular biology and RNA interference (RNAi). More specifically, the present invention relates to specific siRNA molecules, compositions and uses thereof, as well as methods of treating cancer and methods of inhibiting cancer cell proliferation, particularly methods of treating breast cancer. Yet more particularly, the methods of the present invention are methods for inhibiting growth of triple negative breast cancer (TNBC). In a preferred embodiment, the invention provides specific siRNA molecules, comprising a sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, and from any other sequence having a sequence identity greater than 90% between the siRNA and the portion of the target gene. Such siRNA molecules are suitable for the treatment of breast cancer, particularly, TNBC. | 2021-12-30 |
20210403915 | Genetically Modified Mesenchymal Stem Cells for Use in Cardiovascular Prosthetics - A cardiovascular graft is provided, such as a prosthetic heart valve or blood vessel, that comprises mesenchymal stem cells (MSCs) and/or progeny thereof, modified to knock down or knockout expression of the telomerases reverse transcriptase gene (TERT), or otherwise reduce activity of TERT. Also provided are a method of making the cardiovascular graft, and a method of implanting the cardiovascular graft. | 2021-12-30 |
20210403916 | COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION - Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof. | 2021-12-30 |
20210403917 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression. | 2021-12-30 |
20210403918 | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE - The present disclosure relates to compositions and methods for treating liver cancers, especially hepatocellular carcinoma, using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of liver cancer. | 2021-12-30 |
20210403919 | Aptamers For Personal Health Care Applications - An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1). | 2021-12-30 |
20210403920 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER - The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO). | 2021-12-30 |
20210403921 | BIOSYNTHESIS OF MOGROSIDES - Described in this application are enzymes (e.g., cucurbitadienol synthases (CDS), UDP-glycosyltransferases (UGT), C11 hydroxylases, epoxide hydrolases (EPH), squalene epoxidases, and/or cytochrome P450 reductases), host cells expressing the enzymes, and methods of producing mogrol precursors, mogrol, and/or mogrosides using such host cells. | 2021-12-30 |
20210403922 | NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOF - Compositions related to engineered Cas9 enzyme in reducing cellular toxicity and methods using thereof related to the selective targeting and editing endogenous nucleic acid segment in both normal cell and in cell associated with genetic diseases are disclosed. In some cases, a polypeptide comprising a human Exo1 enzyme or a first functional fragment thereof and a Cas9 enzyme or a second functional fragment thereof, which are connected by a linker peptide, is disclosed. In some cases, a polynucleotide encoding the polypeptide and a guide RNA (gRNA) is disclosed. Further, methods for treating single gene disorders utilizing either the polypeptide or the polynucleotide are disclosed. | 2021-12-30 |
20210403923 | MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES - Provided herein are mutant reverse tetracycline transactivator (rtTA) proteins and engineered nucleic acids (e.g., viral vectors, including lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors, and non-viral vectors, including RNA and plasmid DNA) that encode a mutant rtTA that are useful, for example, in regulating gene expression, inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, treating a disease (e.g., acute injuries, neurodegenerative disease, chronic diseases, proliferative diseases, cardiovascular diseases, genetic diseases, inflammatory diseases, autoimmune diseases, neurological diseases, hematological diseases, painful conditions, psychiatric disorders, metabolic disorders, cancers, aging, age-related diseases, and diseases affecting any tissue in a subject), or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, adenoviruses, alphaviruses, vaccinia viruses, retroviruses, herpes viruses, or AAVs) comprising the engineered nucleic acids and methods of regulating (e.g., inhibiting or inducing) cellular reprogramming, tissue repair, tissue regeneration, or any combination thereof by administering an engineered nucleic acid or recombinant virus comprising the same in a cell, tissue or subject (e.g., a cell or tissue of a subject with a condition, which includes any disease (e.g., ocular disease), aging, neurodegenerative diseases, cancer, and age-related diseases) comprising administering a mutant rtTA and an inducible nucleic acid (e.g., an engineered nucleic acid, including an expression vector) encoding a transgene. | 2021-12-30 |
20210403924 | Method for selecting cells based on CRISPR/Cas-mediated integration of a detectable tag to a target protein - Herein is reported a method for providing cells that express a fusion protein from a marker protein and a cell-endogenous target protein, consisting of the steps a) transfecting the cells i) with a Cas9-encoding plasmid additionally containing a nucleic acid which is resistant to a first selection agent, ii) with a circular donor plasmid containing a first nucleic acid which confers resistance to a second selection reagent, and a second nucleic acid which encodes the marker protein and which is flanked 3′ and 5′ by nucleic acids homologous to the integration site in the cell, iii) a suitable synthetic crRNA, and iv) a suitable synthetic tracrRNA, b) cultivating the cells in the presence of the first and the second selection reagent, and c) selecting cells which under the conditions of step b) carry out cell division, and thereby providing/producing cells that express a fusion protein of a marker protein and a cell-endogenous target protein. | 2021-12-30 |
20210403925 | NUCLEIC ACIDS ENCODING CRISPR-ASSOCIATED PROTEINS AND USES THEREOF - The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins. | 2021-12-30 |
20210403926 | METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS AND RNA-BASED ANTIMICROBIALS - The invention relates to the methods for modifying the methylation pattern of bacteriophage DNA and phagemid DNA and to methods for selective killing of bacteria using lysogenic bacteriophages comprising bacteriophage DNA or phagemid DNA comprising components of an engineered CRISPR-Cas system. | 2021-12-30 |
20210403927 | A Recombinant of Hydrogenophilus Bacterium with Enhanced Ability to Produce Valine - bacterium which produces a mutant acetolactate synthase III small subunit formed of a mutant amino acid sequence having an amino acid substitution is able to effectively produce valine through use of carbon dioxide as a sole carbon source. | 2021-12-30 |
20210403928 | Lactic Acid-Producing Hydrogenophilus Bacterium Transformant - A transformant obtained by introducing (a) a lactate dehydrogenase gene and/or (b) a malate/lactate dehydrogenase gene into a | 2021-12-30 |
20210403929 | AN ASPERGILLUS MICROORGANISM CARRYING DISRUPTIONS OF MULTIPLE GENES AND A METHOD OF PRODUCING THEREOF - The objective of the present invention is to provide a transformed | 2021-12-30 |
20210403930 | METHODS FOR CREATING SYNTHETIC CHROMOSOMES EXPRESSING BIOSYNTHETIC PATHWAYS AND USES THEREOF - The present invention encompasses compositions and methods to allow one to deliver and express multiple genes from a biosynthetic pathway in a recipient cell via a synthetic chromosome. | 2021-12-30 |
20210403931 | DETERMINATION OF REGULATORY DNA REGIONS OF ALCOHOL DEHYDROGENASE 3 (ADH3) PROMOTER AND DESIGN OF SYNTHETIC PROMOTERS FOR RECOMBINANT PROTEIN PRODUCTION - The invention relates to the ADH3 promoter, polynucleotide sequences, vectors and expression cassettes including DNA regions responsible for the regulation of the ADH3 promoter; the host cells, including these vectors and expression cassettes, and, the recombinant proteins performed with the developed cells. In the scope of the invention, deletion analyzes in the ADH3 promoter were performed to identify regions that affect promoter strength and significant data was obtained in the formation of mutant ADH3 promoters. Deletion of the nucleotides between 539 and 638 (−361 to −262) in SEQ ID NO: 1 resulted in a 63% increase in ADH3 promoter activity. Five different synthetic promoters were created using positive regulatory regions identified and approximately 165% to 200% promoter activities were achieved with these promoters. | 2021-12-30 |
20210403932 | Plants with Improved Growth - The present invention relates to genetically modified plants comprising a heterologous nucleic acid construct comprising a promoter sequence operably linked to a coding sequence encoding a gene product. The invention further relates to methods for producing such plants. | 2021-12-30 |
20210403933 | SOYBEAN GENE AND USE FOR MODIFYING SEED COMPOSITION - Soybean seeds with increased protein and having a modified expression or activity of at least one or two HECT E3 ligase polypeptides are provided. Methods for modifying expression or activity of HECT E3 ligase polypeptides and polynucleotides include genome editing to modify the transcription regulatory region or sequence encoding the HECT E3 ligase polypeptides and transformation with recombinant DNA constructs to enhance or suppress expression or activity of the HECT E3 ligase polypeptides. Plants containing the modifications produce seeds with altered composition such as one or more of increased protein, decreased soluble carbohydrate, increased oleic acid, decreased saturated fats such as palmitic and stearic acids, and decreased linoleic or linolenic acid. | 2021-12-30 |
20210403934 | AAD-1 EVENT DAS-40278-9, RELATED TRANSGENIC CORN LINES, AND EVENT-SPECIFIC IDENTIFICATION THEREOF - This invention relates in part to plant breeding and herbicide tolerant plants. This invention includes a novel AAD-1 transformation event in corn plants comprising a polynucleotide sequence, as described herein, inserted into a specific site within the genome of a corn cell. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits, including, for example, other herbicide tolerance gene(s) and/or insect-inhibitory proteins. Additionally, the subject invention provides assays for detecting the presence of the subject event in a sample (or corn grain, for example). The assays can be based on the DNA sequence of the recombinant construct, inserted into the corn genome, and on the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are also provided. | 2021-12-30 |
20210403935 | HERBICIDE RESISTANT PLANTS - The present invention relates to plants having resistance to PPO inhibiting herbicides such as the herbicide oxyfluorfen conferred by a loss of function of one or more sulfolipid biosynthesis enzymes involved in the sulfolipid biosynthesis pathway and methods of producing said plants. The invention also relates to methods of producing a plant having resistance to PPO inhibiting herbicides, including but not limited to the herbicide oxyfluorfen, by modulating the expression of one or more sulfolipid biosynthesis genes and/or function of one or more sulfolipid biosynthesis enzymes involved in the sulfolipid biosynthesis pathway, and to plants produced by the methods. | 2021-12-30 |
20210403936 | USE OF YR4DS GENE OF AEGILOPS TAUSCHII IN STRIPE RUST RESISTANCE BREEDING OF TRITICEAE PLANTS - A Yr4DS gene of | 2021-12-30 |
20210403937 | CMV RESISTANCE ALLELE - The present invention relates to an allele designated alpha-CMV which confers resistance to CMV when present in a spinach plant, wherein the protein encoded by said allele is a CC-NBS-LRR protein that comprises in its amino acid sequence: a) the motif “MAEIGYSVC” (SEQ ID NO: 22) at its N-terminus; and b) the motif “KWMCLR” (SEQ ID NO: 23); and c) an LRR domain that has in order of increased preference at least 95%, 96%, 97%, 98%, 99%, 100% sequence similarity to SEQ ID NO: 10. The allele has a genomic nucleotide sequence which in order of increased preference has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% sequence similarity to SEQ ID NO: 1. The invention further relates to plants comprising the allele and to various methods involving the allele. | 2021-12-30 |
20210403938 | INSECTICIDAL PROTEINS - Compositions and methods for controlling plant pests are disclosed. In particular, novel insecticidal proteins having toxicity Coleopteran and/or Lepidopteran insect pests are provided. Nucleic acid molecules encoding the novel insecticidal proteins are also provided. Methods of making the insecticidal proteins and methods of using the insecticidal proteins and nucleic acids encoding the insecticidal proteins of the invention, for example in transgenic plants to confer protection from insect damage, are also disclosed. | 2021-12-30 |
20210403939 | COPI COATOMER GAMMA SUBUNIT NUCLEIC ACID MOLECULES THAT CONFER RESISTANCE TO COLEOPTERAN AND HEMIPTERAN PESTS - This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby. | 2021-12-30 |
20210403940 | METHOD AND FORMULATION FOR INDUCING ABORTION OR DEFORMATION OF PLANT SEEDS - The present disclosure relates to the field of genetic breeding, in particular, to methods and formulations for inducing abortion or deformation of plant seeds by a VvDUF642 gene. The result of the present disclosure shows that the VvDUF642 gene is continuously expressed at a high level in seedless varieties, but there is no significant change in expression in nucleated varieties. After the VvDUF642 gene is transformed into an | 2021-12-30 |
20210403941 | NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS - The present invention relates to a polynucleotide comprising at least one promoter and an S/MAR element, wherein said S/MAR element is located downstream of said promoter and wherein the nucleic acid sequence of said S/MAR element (S/MAR sequence) comprises at least 3sequence motifs ATTA (SEQ ID NO:1) per 100 nucleotides over a stretch of at most 200 nucleotides; the present invention further relates to a composition and to a host cell comprising said polynucleotide, and to the polynucleotide for use in medicine and for use in treating genetic disease. The present invention also relates to a kit and to a device comprising said polynucleotide, and to methods and uses related to the polynucleotide. | 2021-12-30 |
20210403942 | SYSTEMS FOR CELL CONTROL - The disclosure relates to growing cells, directing cells to grow into specified cell types, genetically and physically manipulating cells, and addressing one or more individual cells within a mixed cell population. Aspects of the disclosure relate to vectors useful to induce developmental changes in cells, in which those vectors have a temporal component. Vectors of the disclosure encode a controllable, temporal series of events. Once the vectors are delivered into target cells, a series of discrete and different genetic events may be induced. The disclosed methods generally provide for the temporal encoding of multiplex genetic effectors in vector format for cell state transitions. | 2021-12-30 |
20210403943 | TARGETED INTEGRATION OF NUCLEIC ACIDS - The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins wherein those TI host cells have been subjected to supertransfection resulting in the random integration (RI) of exogenous nucleic acids encodes into their genome, as well as methods of producing and using said supertransfected TI host cells. | 2021-12-30 |
20210403944 | Circular RNA For Translation In Eukaryotic Cells - Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5′ homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed. | 2021-12-30 |
20210403945 | COMPOSITIONS AND METHODS UTILIZING GENETICALLY-MODIFIED ANIMALS AND CELLS - Provided herein are compositions and methods for studying cancer therapeutics and etiology, for example, mouse cancer models, cancer cell lines, and uses thereof. Human p53 knock-in (Hupki) mice with a Y220 (e.g., Y220C, Y220H, or Y220S) mutation in p53 are provided. These Hupki-Y220 mice can be used, for example, to examine tumorigenesis in different tissues, investigate mechanisms of gain of function, develop mouse models of cancer, generate cancer cell lines that can be implanted into recipient mice, and test potential therapeutics. | 2021-12-30 |
20210403946 | MACHINE LEARNING ACCELERATED PROTEIN ENGINEERING THROUGH FITNESS PREDICTION - Techniques for identifying production-fit amino acid sequence libraries are disclosed. The techniques may include accessing a statistical model relating an input amino acid sequence to production fitness of a protein having the input amino acid sequence, obtaining production fitness information for production-fit variant amino acid sequences, and generating an amino acid sequence library having amino acid sequences with predicted production fitness in accordance with the production fitness information. The techniques further include using a statistical model for a protein characteristic other than production fitness to generate an amino acid sequence library having amino acid sequences that are both predicted to be production-fit and have the protein characteristic. | 2021-12-30 |
20210403947 | MINIATURIZED DYSTROPHINS AND USES THEREOF - Disclosed herein are nucleic acid molecules, polypeptides, cells, vectors, and pharmaceutical compositions relating to miniaturized dystrophin. Methods of production and methods of therapeutic use of the miniaturized dystrophin are also disclosed. | 2021-12-30 |
20210403948 | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof - The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly liver-directed gene therapy, and for vaccination purposes. | 2021-12-30 |
20210403949 | VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA - Viral vectors, lentiviral particles, and modified cells are disclosed. They encode or express a small RNA capable of targeting the KIF11 gene. In embodiments, the viral vectors and lenti viral particles further comprise and a KIF11 gene whose non-coding region has been modified such that it is resistant to activity by the small RNA. | 2021-12-30 |
20210403950 | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE - The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer. | 2021-12-30 |
20210403951 | Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis - The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising | 2021-12-30 |
20210403952 | METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF - The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents. | 2021-12-30 |
20210403953 | TARGETED INTEGRATION OF NUCLEIC ACIDS - The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins wherein those TI host cells have been subjected to supertransfection resulting in the random integration (RI) of exogenous nucleic acids encodes into their genome, as well as methods of producing and using said supertransfected TI host cells. | 2021-12-30 |
20210403954 | METHOD OF PRODUCING ISOPRENOID COMPOUND - Producing an isoprenoid compound by:
| 2021-12-30 |
20210403955 | METHOD TO USE INDUSTRIAL CO2 CONTAINING GAS FOR THE PRODUCTION OF A METHANE ENRICHED GAS COMPOSITION - The present invention refers to a method using CO | 2021-12-30 |
20210403956 | METHODS FOR PRODUCING ISOBUTENE FROM 3-METHYLCROTONIC ACID - Described are methods for the production of isobutene comprising the enzymatic conversion of 3-methylcrotonic acid into isobutene wherein said 3-methylcrotonic acid is obtained by the enzymatic conversion of 3-methylcrotonyl-CoA into 3-methylcrotonic acid or wherein said 3-methylcrotonic acid is obtained by the enzymatic conversion of 3-hydroxyisovalerate (HIV) into 3-methylcrotonic acid. It is described that the enzymatic conversion of 3-methylcrotonic acid into isobutene can, e.g., be achieved by making use of a 3-methylcrotonic acid decarboxylase, preferably an FMN-dependent decarboxylase associated with an FMN prenyl transferase, an aconitate decarboxylase (EC 4.1.1.6), a methylcrotonyl-CoA carboxylase (EC 6.4.1.4), or a geranoyl-CoA carboxylase (EC 6.4.1.5). | 2021-12-30 |
20210403957 | APPLICATION OF TREHALASE IN FERMENTATIVE PRODUCTION - Provided is an application of trehalase in fermentative production. The trehalase has amino acid sequences shown in SEQ ID NO.6, SEQ ID NO.7, and SEQ ID NO.8. Provided are methods for producing and applying trehalase, particularly being applied in the production and fermentation of alcohol and an amino acid. | 2021-12-30 |
20210403958 | SYSTEM AND METHOD FOR PRODUCING FUEL GRADE ETHANOL FROM CELLULOSIC AND HIGH STARCH COMBINED FEEDSTOCKS - Ethanol is produced by the simultaneous production of both First and Second generation (1G, 2G) fuel grade ethanol in the same production plant. A First Generation feedstock such as corn is continuously fed to the first generation section and a lignocellulosic feedstock such as corn stover from the 1G corn is supplied to the second generation area Thus, there is a common fermentation area for both the C5 and C6 sugar fermentation. The invention can economically be best implemented in places where there are incentives offered for the use of various feedstocks. Specifically, the invention allows the D3 rin to be maximized in an existing first-generation ethanol plant with the installation of the front end of the 2G equipment. | 2021-12-30 |
20210403959 | USE OF TYPE I AND TYPE II POLYKETIDE SYNTHASES FOR THE PRODUCTION OF CANNABINOIDS AND CANNABINOID ANALOGS - The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important prenylated polyketides of the cannabinoid family. Using readily available starting materials, heterologous enzymes are used to direct cannabinoid biosynthesis in yeast. | 2021-12-30 |
20210403960 | SYSTEMS AND METHODS FOR PRODUCING POLYHYDROXYALKANOATES FROM ORGANIC WASTE - Systems and methods are provided for cost effective biosynthesis of polyhydroxyalkanoates (PHA) that have desirable material properties similar to petrochemically derived plastics. Synthesis takes place intracellularly in extreme halophiles grown in saline conditions that selectively reduces contamination from other microbes. The industrial scale PHA production systems use low-cost organic waste feedstocks, spent medium treatment and recycling and enzyme recovery and reuse for efficiency and reduced cost compared to existing processes. | 2021-12-30 |
20210403961 | POLYHYDROXYALKANOATE PRODUCTION METHODS AND MATERIALS AND MICROORGANISMS USED IN SAME - Embodiments of the invention relate generally to methods to generate microorganisms and/or microorganism cultures that exhibit the ability to produce polyhydroxyalkanoates (PHA) from carbon sources at high efficiencies. In several embodiments, preferential expression of, or preferential growth of microorganisms utilizing certain metabolic pathways, enables the high efficiency PHA production from carbon-containing gases or materials. Several embodiments relate to the microorganism cultures, and/or microorganisms isolated therefrom. | 2021-12-30 |
20210403962 | MODIFIED HOMOSERINE DEHYDROGENASE AND METHOD FOR PRODUCING HOMOSERINE OR L-AMINO ACID DERIVED FROM HOMOSERINE USING THE SAME - The present disclosure relates to modified homoserine dehydrogenase and a method for producing a homoserine-derived L-amino acid using the same. | 2021-12-30 |
20210403963 | CYSTEINE POLYSULFIDATION AND MITOCHONDRIAL BIOENERGETICS REGULATED BY CYSTEINYL-tRNA SYNTHETASE - A method of synthesize cysteine hydropersulfide (CysSSH) includes taking a substrate L-cysteine, and performing a reaction catalyzed by cysteinyl-tRNA synthetases (CARSs). | 2021-12-30 |
20210403964 | CANNABINOID PRODUCTION IN ALGAE - An expression system and method for producing a cannabinoid in algae are provided. The method includes expressing in an algae cell an enzyme for converting hexanoic acid to hexanoyl-CoA, enzymes for converting hexanoyl-CoA to olivetolic acid (OA), an enzyme for converting olivetolic acid (OA) to cannabigerolic acid (CbGA) and an enzyme for converting cannabigerolic acid (CbGA) to a cannabinoid. | 2021-12-30 |
20210403965 | PRODUCTION OF CANNABINOIDS IN YEAST - The present disclosure relates to the production of cannabinoids in yeast. In as aspect there is provided a genetically modified yeast comprising: one or more GPP producing genes and optionally, one or more GPP pathway genes; two or more olivetolic acid producing genes; one or more cannabinoid precursor or cannabinoid producing genes; one or more Hexanoyl-CoA producing genes, and at least 5% dry weight of fatty acids or fats. | 2021-12-30 |
20210403966 | METHOD FOR PREPARING CRUDE POLYSACCHARIDE BASED ON SYNERGISTIC FERMENTATION OF CORN STOVER AND FUNGUS - The application discloses a method for preparing crude polysaccharides based on synergistic fermentation with corn stover and fungus, including the following steps: step (1): drying corn stover, pulverizing, placing in a hydrothermal reactor, adding deionized water, sealing the hydrothermal reactor, placing in a heating device, reacting, taking out reaction products, centrifuging and drying a solid; step (2): adding the products obtained in step (1) and dried bean curd residue to a container, adding distilled water, mixing uniformly, sterilizing to obtain a mixed material, inoculating a fungus inoculum under aseptic conditions, sealing the container and cultivating in the dark to obtain crude polysaccharides. The disclosure uses corn stover and bean curd residue as raw materials to achieve efficient utilization of discarded biomass, reduce environmental pollution, and improve utilization of corn stover. | 2021-12-30 |
20210403967 | DIETARY FIBER PRODUCTION USING A GLYCOSYL-TRANSFERASE - Methods are disclosed for the production of soluble dietary fiber from a starch, including, e.g., corn and wheat starch. The methods comprise adding an acid to a soluble starch, mixing and heating the starch to form a starch substrate, and placing the starch substrate in contact with a glycosyl-transferase, thus producing a soluble dietary fiber composition having a higher a higher soluble dietary content than a composition without the addition of the glycosyl-transferase. | 2021-12-30 |
20210403968 | MICROELECTRODE ARRAY WITH A SWITCHABLE HYDROPHILIC SURFACE - A switchable hydrophilic surface is created by attaching electrochemically switchable hydrophilicity polymers to the surface of a microelectrode array. Ferrocene polymers are one example of electrochemically switchable hydrophilicity polymers. Activation of electrodes in the microelectrode array changes the oxidation state of metal ions which switches the polymers between hydrophobic and hydrophilic conformations. Selective activation of electrodes can create patterns of wettability on the microelectrode array that may be varied in real time. The switchable hydrophilic surface may be used to control solid-phase synthesis of polymers. Growing polymers may be selectively extended at locations on the microelectrode array that are hydrophilic. The pattern of hydrophobic and hydrophilic regions can be changed during sequential rounds of synthesis to create a variety of different polymers at different locations on the surface of the microelectrode array. | 2021-12-30 |
20210403969 | ENHANCED PRODUCTION OF RHAMNOLIPIDS USING AT LEAST TWO CARBON SOURCES - Provided is a method for improving the yield of rhamnolipids comprising culturing in medium containing a triglyceride containing oil and sweetener as a carbon source. | 2021-12-30 |